Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML - Seite 2

“Publication in this prestigious, peer-reviewed journal not only highlights the profound need for better JMML treatment outcomes, but it further speaks to the powerful utility of Notable’s PPMP predicting treatment outcome, as demonstrated for other diseases,” said Thomas Bock, M.D., Chief Executive Officer of Notable. “In addition to identifying potentially more effective pre-HSCT drug combinations, these data may also serve as a valuable database for researchers and physicians by detailing the ex vivo effects of 130 drug combinations on JMML leukemic cells to prioritize therapeutic regimens for future clinical study and advance the standard of care.”

The research article, titled “Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay” was first-authored by Dr. Elliot Stieglitz, M.D., Associate Professor at UCSF Benioff Children’s Hospital (UCSF, https://profiles.ucsf.edu/elliot.Stieglitz).

“This publication marks the culmination of a multi-year collaboration between UCSF and Notable Labs,” remarked Dr. Stieglitz. “The ex vivo study described in the research article represents the largest high-throughput drug screen using primary samples conducted to date in this rare disease and will serve as a blueprint for researchers trying to bring novel combinations of medications to the clinic.”

About Notable Labs, Inc.

Notable Labs, Inc. is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (“PPMP”), Notable bio- simulates a cancer treatment and predicts whether or not a patient is likely to respond to that specific therapeutic. Notable’s PPMP can identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. By continually advancing and expanding the reach of the PPMP across diseases and predicted medical outcomes, Notable aims to be the leader in precision medicine and revolutionize the way in which patients seek and receive treatments that work best for them – patient by patient and cancer by cancer. Notable believes it has created a targeted and de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, higher, and with a greater likelihood of success than traditional drug development. By transforming historical standards of care, Notable aims to create dramatic positive impact for patients and the healthcare community. Notable is headquartered in Foster City, California. Learn more at www.notablelabs.com and follow us @notablelabs.

CONTACTS:

Investor Relations: Daniel Ferry, LifeSci Advisors

[phone], [e-mail]